Immunic expects to fund operations into late 2027 with $200M from a private placement, targeting NDA submission in mid-2027 and regulatory approval in 2028 for vidofludimus calcium.
Bullish
Immunic secured $200M in private placement funding, extending its operational runway into late 2027. The company strengthened its leadership team and progressed vidofludimus calcium in Phase 3 trials and pipeline expansion.
Bearish
Immunic experienced increased R&D and G&A expenses, leading to a wider net loss of $32.6M for Q1 2026. The company is also exploring strategic alternatives for its IMU-856 program.